Cong LIU

Founder & Chief Scientific Officer

Fully responsible for the company's scientific development strategy.

Bachelor's degree from Jilin University, Ph.D. from Peking University, Postdoctoral fellow at University of California, Los Angeles & Howard Hughes Medical Institute. Returned to China in 2013 and joined the Center for Chemical and Biological Sciences at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, serving as a researcher and doctoral supervisor.

Dr. Cong Liu's research focuses on the use of chemical and biological interdisciplinary methods to study the mechanism of protein self-assembly and aggregation and its pathogenic role in neurodegenerative diseases. Research is conducted in three directions: the structural basis of pathological protein aggregation, the mechanism of interaction between chemical molecules and protein aggregates, and the development of molecular probes targeting pathological protein aggregation. In the past five years, more than 80 SCI papers have been published related to this work.

Mengqi FAN

Board Member & Chief Executive Officer

Fully responsible for the global strategic planning, business development, and company operations of SynuSight Biotech.

Mr. Mengqi Fan graduated from Fudan University and has extensive experience in enterprise management and project operations, with many years of research and professional experience in bioinformatics and artificial intelligence. Before joining SynuSight Biotech, he served as the Vice President of the Biopharmaceutical Business Group at Shenshi Technology, responsible for the company's early product operations and external cooperation. During his tenure, he led the team to achieve BD cooperation with hundreds of domestic and foreign innovative pharmaceutical companies and research institutions, successfully building Shenshi Technology as an industry leader in AI for Science in the biopharmaceutical field.

Jiang BIAN

Head of the Discovery

Junying YUAN

Chairman of the Scientific Advisory Board

Provides strategic advice and academic support for the pipeline development of SynuSight.

Bachelor's degree in Biochemistry from Fudan University, Ph.D. from Harvard Medical School, studied under Nobel laureate Professor Robert Horvitz, Foreign Academician of the Chinese Academy of Sciences, Member of the National Academy of Sciences, USA, Director of the Center for Chemical and Biological Sciences at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

Academician Junying Yuan has been engaged in the study of cell death mechanisms for many years and is one of the pioneers in the field of cell death research worldwide. She is the discoverer of the world's first cell death gene, which laid the research foundation for the field of apoptosis research worldwide, prompting numerous laboratories around the world to systematically study apoptosis from different perspectives. Professor Yuan is the discoverer of programmed necrosis in cells and has explained how cell necrosis is regulated from the levels of chemical biology and cell biology. In recognition of Professor Yuan's significant contributions to the field of cell death, she has been invited by the Nobel Prize Committee to give special lectures on multiple occasions. Her work made a significant contribution to her mentor Dr. H.R. Horvitz's receipt of the 2002 Nobel Prize. She has received various international outstanding research awards such as the Ryan Fellowship, Wilson S. Stone Memorial Award, The SCBA Outstanding Young Investigator Award, and is recognized as an authority in the field of cell death research by the international academic community.

Dan LI

Scientific Advisory Board Member

Vice President of the School of Life Sciences and Technology, Shanghai Jiao Tong University, Executive Dean of Bio-X Research Institute, Young Talent of the Ten Thousand Talents Program. Professor Dan Li's research focuses on the role of pathological protein phase separation/phase transition in neurodegenerative diseases and the study of tracing and regulating pathological protein phase transition aggregation through chemical means.

Developing and applying biophysical, biochemical, and cell biological techniques to elucidate the molecular mechanisms by which protein phase regulation disorders lead to abnormal aggregation and the formation of pathological aggregates, and their relationship with neurodegenerative diseases, revealing the pathogenic mechanisms of abnormal aggregation of key pathogenic proteins in various neurodegenerative diseases, and achieving in situ tracing of pathological protein aggregates through rational design of chemical molecules. The molecular tracers developed are currently in preclinical development. In the past five years, Professor Dan Li has published more than 60 SCI papers, cited more than 3,500 times (Google Scholar). As (co-)corresponding author, he has published more than 30 SCI papers in high-level journals such as Cell, Cell Research, Cell Reports, PNAS, Nature Chemical Biology, Nature Structural & Molecular Biology, Nature Communications, eLife. He has successively presided over major integrated projects and general projects of the National Natural Science Foundation of China.